Literature DB >> 8403509

In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV.

A Carr1, B Tindall, R Penny, D A Cooper.   

Abstract

Hypersensitivity to trimethoprim-sulphamethoxazole (TMP-SMX) in patients with HIV infection may be a result of either immune dysregulation, a direct cytotoxicity of the SMX-hydroxylamine metabolite (SMX-HA) (rather than SMX per se), or glutathione deficiency. We evaluated the in vitro cytotoxicity of SMX and SMX-HA to peripheral blood mononuclear cells (PBMC) of HIV-infected subjects to determine if the degree of in vitro cytotoxicity is associated with hypersensitivity, whether glutathione inhibits cytotoxicity, and whether in vitro cytotoxicity is predictive for the development of hypersensitivity. Given that fever is often a prominent feature of hypersensitivity, we also assessed whether SMX or SMX-HA could induce the in vitro production of IL-1 beta, IL-6 or tumour necrosis factor-alpha (TNF-alpha) by PBMC. The cytotoxicities of SMX and SMX-HA to PBMC were assessed in 45 HIV-infected patients with prior TMP-SMX therapy, and in eight HIV- controls. Twelve HIV-infected subjects were studied prospectively before primary Pneumocystis carinii pneumonia (PCP) therapy or rechallenge with TMP-SMX in previously hypersensitive subjects. Cytokine production was measured in four hypersensitive and two non-hypersensitive HIV-infected subjects, and three HIV-uninfected controls. The cytotoxicity of SMX-HA to PBMC was significantly greater in the 22 HIV-infected patients with prior hypersensitivity than both the 23 HIV-infected patients without hypersensitivity and the control group. Cytotoxicity was significantly reduced by glutathione only in the hypersensitive group. SMX did not induce cytotoxicity in any group. In 12 subjects studied prospectively, SMX-HA cytotoxicity was also significantly greater in those with subsequent hypersensitivity. Exposure of PBMC to SMX-HA resulted in a modest increase in the production of IL-6, IL-1 beta and TNF-alpha, although no major difference was detected between subjects with or without hypersensitivity. These data suggest that SMX-HA and glutathione deficiency are involved in the pathogenesis of hypersensitivity to TMP-SMX in HIV-infected patients, and that in vitro cytotoxicity could be useful in the diagnosis of hypersensitivity and predicting its likelihood.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8403509      PMCID: PMC1534391          DOI: 10.1111/j.1365-2249.1993.tb05971.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Trimethoprim-sulfamethoxazole treatment of Pneumocystis carinii pneumonia in adults.

Authors:  W K Lau; L S Young
Journal:  N Engl J Med       Date:  1976-09-23       Impact factor: 91.245

2.  Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma.

Authors:  R Mitsuyasu; J Groopman; P Volberding
Journal:  N Engl J Med       Date:  1983-06-23       Impact factor: 91.245

3.  Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients.

Authors:  H Jick
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr

4.  A coordinated approach to children's health in India: progress report after five years (1975-1980).

Authors: 
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

5.  Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial.

Authors:  J M Wharton; D L Coleman; C B Wofsy; J M Luce; W Blumenfeld; W K Hadley; L Ingram-Drake; P A Volberding; P C Hopewell
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

6.  Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.

Authors:  J A Kovacs; J W Hiemenz; A M Macher; D Stover; H W Murray; J Shelhamer; H C Lane; C Urmacher; C Honig; D L Longo
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

7.  Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.

Authors:  F M Gordin; G L Simon; C B Wofsy; J Mills
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

8.  Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia.

Authors:  D J Winston; W K Lau; R P Gale; L S Young
Journal:  Ann Intern Med       Date:  1980-06       Impact factor: 25.391

9.  Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients.

Authors:  A Carr; R Penny; D A Cooper
Journal:  AIDS       Date:  1993-01       Impact factor: 4.177

10.  Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity.

Authors:  N H Shear; S P Spielberg; D M Grant; B K Tang; W Kalow
Journal:  Ann Intern Med       Date:  1986-08       Impact factor: 25.391

View more
  15 in total

Review 1.  Role of bioactivation in drug-induced hypersensitivity reactions.

Authors:  Joseph P Sanderson; Dean J Naisbitt; B Kevin Park
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

Review 2.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

3.  Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity.

Authors:  D J Naisbitt; S J Hough; H J Gill; M Pirmohamed; N R Kitteringham; B K Park
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

4.  Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients.

Authors:  Hideaki Kagaya; Masatomo Miura; Takenori Niioka; Mitsuru Saito; Kazuyuki Numakura; Tomonori Habuchi; Shigeru Satoh
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

Review 5.  Mechanisms of unpredictable adverse drug reactions.

Authors:  M J Rieder
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

6.  A novel two-step hierarchical quantitative structure-activity relationship modeling work flow for predicting acute toxicity of chemicals in rodents.

Authors:  Hao Zhu; Lin Ye; Ann Richard; Alexander Golbraikh; Fred A Wright; Ivan Rusyn; Alexander Tropsha
Journal:  Environ Health Perspect       Date:  2009-04-03       Impact factor: 9.031

7.  HIV Tat potentiates cell toxicity in a T cell model for sulphamethoxazole-induced adverse drug reactions.

Authors:  Kemi Adeyanju; Adriana Krizova; Philippe A Gilbert; Gregory A Dekaban; Michael Rieder
Journal:  Virus Genes       Date:  2009-03-10       Impact factor: 2.332

8.  Immune response to sulfamethoxazole in patients with AIDS.

Authors:  M P Daftarian; L G Filion; W Cameron; B Conway; R Roy; F Tropper; F Diaz-Mitoma
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

9.  Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection.

Authors:  A Carr; E Vasak; V Munro; R Penny; D A Cooper
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

Review 10.  In vitro analysis of metabolic predisposition to drug hypersensitivity reactions.

Authors:  R J Riley; J S Leeder
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.